Unique ID issued by UMIN | UMIN000001351 |
---|---|
Receipt number | R000001643 |
Scientific Title | Open-label randomized comparative study of cefotiam vs. ampicillin/sulbactam in adults with mild to moderate community-acquired pneumonia |
Date of disclosure of the study information | 2008/09/30 |
Last modified on | 2021/09/13 12:04:35 |
Open-label randomized comparative study of cefotiam vs. ampicillin/sulbactam in adults with mild to moderate community-acquired pneumonia
Comparative study of cefotiam vs. ampicillin/sulbactam in adult community-acquired pneumonia
Open-label randomized comparative study of cefotiam vs. ampicillin/sulbactam in adults with mild to moderate community-acquired pneumonia
Comparative study of cefotiam vs. ampicillin/sulbactam in adult community-acquired pneumonia
Japan |
Community-acquired pneumonia
Pneumology | Infectious disease |
Others
NO
To compare clinical effectiveness between cefotiam and ampicillin/sulbactam in adult patients with mild to moderate community-acquired pneumonia.
Bio-equivalence
Confirmatory
Pragmatic
Phase IV
Clinical response at the end of therapy, days 11-14
Early clinical response at days 4 and 7
Bacteriological response at days 11-14 (in bacteriologically evaluable patients)
Survival at day 30
Interventional
Parallel
Randomized
Individual
Open -but assessor(s) are blinded
Active
NO
NO
Institution is not considered as adjustment factor.
NO
Pseudo-randomization
2
Treatment
Medicine |
cefotiam 1g IV, every 12 hrs, for 4-14 days.
Clarithromycin 200mg PO, bid, for 4-14 days.
May be adjusted when renal failure.
ampicillin/sulbactam 3g IV, every 12 hrs, for 4-14 days.
Clarithromycin 200mg PO, bid, for 4-14 days.
May be adjusted when renal failure.
15 | years-old | <= |
Not applicable |
Male and Female
(1) Patients with community-acquired pneumonia aged 15 yrs or more
(2) Radiological appearance of a new and/or progressive pulmonary infiltrate(s)
(3) At least two of the followings: cough, sputum or change of sputum character (increased volume and/or purulence), dyspnea, tachypnea, abnormal breathing sound (wheeze etc.), pleuritic chest pain, auscultatory findings on chest examination consistent with the lung infiltrate, documented axillary body temperature > or = 37.5C within the past 24hrs, rigors and/or chills, general malaise, and a WBC count of > or = 10,000/mm3 or < 3,000/mm3.
(1) Hospital-acquired pneumonia
(2) Hospitalization within 60 days prior to the development of the symptom(s)
(3) Immunocompromising disease or receipt of immunopompromising therapy
(4) Active lung cancer
(5) Terminal illness
(6) Pregnancy or breast-feeding
(7) Known allergy to the indicated antibiotics
(8) Other infiltrative diseases (e.g. radiation pneumonitis, organizing pneumonia, drug-induced pneumonia, obstructive pneumonia etc.)
(9) Tuberculosis, fungal infection
(10) Empyema
(11) Aspiration pneumonia
120
1st name | |
Middle name | |
Last name | Isao Ito |
Kyoto University
Department of Respiratory Medicine
54 Shogoin-kawaharacho, Sakyo, Kyoto, 606-8507, Japan
075-751-3884
1st name | |
Middle name | |
Last name | Seizo Kadowaki |
Ono Municipal Hospital
Department of Internal Medicine
323 Nakamachi, Ono-city, 675-1332, Japan
0794-63-2020
Ono Municipal Hospital
Dainippon Sumitomo Pharma Co., Ltd.
Taisho Toyama Pharmaceutical Co., Ltd.
Profit organization
Japan
NO
2008 | Year | 09 | Month | 30 | Day |
Unpublished
Completed
2008 | Year | 06 | Month | 13 | Day |
2008 | Year | 09 | Month | 01 | Day |
2008 | Year | 09 | Month | 01 | Day |
2013 | Year | 04 | Month | 30 | Day |
2008 | Year | 09 | Month | 03 | Day |
2021 | Year | 09 | Month | 13 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000001643